# Effect of Genotype-Guided Oral P2Y12 Inhibitor Selection vs Conventional Clopidogrel Therapy in Symptomatic ICAD

> **NCT06714526** · NA · RECRUITING · sponsor: **Sunnybrook Health Sciences Centre** · enrollment: 100 (estimated)

## Conditions studied

- Intracranial Atherosclerosis

## Interventions

- **GENETIC:** Point-of-Care CYP2C19 Testing
- **DRUG:** ticagrelor + aspirin
- **DRUG:** clopidogrel + aspirin

## Key facts

- **NCT ID:** NCT06714526
- **Lead sponsor:** Sunnybrook Health Sciences Centre
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-10-07
- **Primary completion:** 2027-08
- **Final completion:** 2027-08
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2025-11-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06714526

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06714526, "Effect of Genotype-Guided Oral P2Y12 Inhibitor Selection vs Conventional Clopidogrel Therapy in Symptomatic ICAD". Retrieved via AI Analytics 2026-07-05 from https://api.ai-analytics.org/clinical/NCT06714526. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*